Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
Abroad (travel likely)RecruitingPHASE3
Conditions
Primary Immune Thrombocytopenia (ITP)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Henri Mondor Hospital, Créteil, France
Contact: Study coordinator (MAHEVAS Matthieu, PHD)